Non Alcoholic Steatohepatitis

Terns Reports Topline Results from Early-Stage NASH Study

89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health

Why Are Intercept Pharmaceuticals Shares Falling Today?

89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health

Why Are Intercept Pharmaceuticals Shares Falling Today?

Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead

Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor

|

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead

|

Terns' Potential NASH Candidate Shows Potent Liver Target Engagement

|

Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement

|

Non Alcoholic Steatohepatitis Recent News

Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients

|

Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial

|

Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022

|

Axcella To Test NASH Candidate In Long COVID Patients

|

Enanta To Discontinue Internal Development Of NASH Candidates

|

Fast Track Status Expanded For Inventiva's NASH Treatment

|

Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial.

|

Why Are Hepion Pharma Shares Moving Higher Premarket Monday?

|

Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial

Lipocine Inc (NASDAQ: LPCN) has

|

Siemens' Fatty Liver Disease Blood Test Wins FDA De Novo Clearance

|

Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients

|

89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference

89bio Inc (NASDAQ: ETNB)

|

A Primer On NASH

|